Presidio Capital Management LLC Makes New $527,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Presidio Capital Management LLC bought a new stake in Edwards Lifesciences Co. (NYSE:EW) in the third quarter, HoldingsChannel.com reports. The firm bought 7,992 shares of the medical research company’s stock, valued at approximately $527,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Empirical Finance LLC grew its stake in Edwards Lifesciences by 3.4% during the first quarter. Empirical Finance LLC now owns 22,046 shares of the medical research company’s stock worth $2,107,000 after buying an additional 732 shares in the last quarter. Empowered Funds LLC increased its stake in Edwards Lifesciences by 151.2% in the first quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock valued at $1,923,000 after acquiring an additional 12,112 shares during the last quarter. SG Americas Securities LLC raised its position in Edwards Lifesciences by 236.4% during the first quarter. SG Americas Securities LLC now owns 97,554 shares of the medical research company’s stock valued at $9,322,000 after purchasing an additional 68,556 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Edwards Lifesciences by 14.3% during the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 25,792 shares of the medical research company’s stock worth $2,465,000 after purchasing an additional 3,221 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in shares of Edwards Lifesciences by 23.4% in the 1st quarter. Oppenheimer & Co. Inc. now owns 26,253 shares of the medical research company’s stock valued at $2,509,000 after purchasing an additional 4,977 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 0.1 %

Edwards Lifesciences stock opened at $65.84 on Friday. The firm has a 50 day simple moving average of $67.75 and a 200 day simple moving average of $77.18. The firm has a market capitalization of $39.66 billion, a price-to-earnings ratio of 9.50, a P/E/G ratio of 3.74 and a beta of 1.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.59 earnings per share. On average, analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Stifel Nicolaus reduced their price objective on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Robert W. Baird decreased their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Barclays decreased their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Finally, The Goldman Sachs Group dropped their price target on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $75.67.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,250 shares of company stock valued at $2,746,988. Corporate insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.